← Trials/Trial dossier/NCT00065169

CompletedPhase NA

Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs

Anti-Inflammation in AD: PET Imaging Supplement

Lead sponsor

University of California, Los Angeles

Asset

Celecoxib

Listed sites

Recruiting sites

Enrollment

138

Study population

Alzheimer’s disease

Key I/E criteria

•MMSE 26-30•MRI contraindications excluded

Primary endpoint

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

SecondaryDSIR AT-GP

NCT IDNCT00065169

Org study IDR01MH058156https://reporter.nih.gov/quickSearch/R01MH058156

NihR01MH058156

Timeline

Milestones

Study start2000-11 (month precision)

Study first posted2003-07-18estimated

Primary completion2005-11actual (month precision)

Study completion2005-11actual (month precision)

Last update posted2020-03-02actual

Assets

Drug assets

Celecoxib

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age40 Years

Maximum age90 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•NIMH diagnostic criteria for Age Associated Memory Impairment (AAMI)

•Mini-Mental State Examination (MMSE) score between 26 and 30 (unless < 8 years of educational achievement)

•No significant cerebrovascular disease

•Estrogen replacement therapy and thyroid replacement therapy (if the participant is euthyroid) are permitted if the therapies are stable for > 1 month

•Memory and verbal fluency cut-off scores that increase the probability of incipient dementia (Buschke-Fuld: 34; verbal fluency: 46 for letters, 7 for categories; Benton Visual Retention: 5)

•Adequate visual and auditory acuity to allow neuropsychological testing

•Normal screening laboratory tests and electrocardiogram (ECG)

Exclusion criteria

•Possible or probable Alzheimer Disease (AD) or other dementia

•Neurologic or other physical illness that could produce cognitive deterioration

•History of transient ischemic attacks (TIAs), carotid bruits, or lacunes on an MRI scan

•History of myocardial infarction within the previous year or unstable cardiac disease

•Uncontrolled hypertension (systolic BP > 170 or diastolic BP > 100)

•History of significant liver disease, pulmonary disease, diabetes, or cancer

•DSM-IV criteria for major psychiatric disorders within the previous 2 years

•Past or present history of alcoholism or drug dependence

•Untreated depression as determined by a Hamilton Depression Rating Scale (HAM-D) score of 12 or more

•Drugs that may significantly affect psychometric test results

•Centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, antipsychotics, benzodiazepines, systemic corticosteroids, medications with significant cholinergic or anticholinergic effects, anti-convulsants, warfarin, vitamins other than the standard multivitamin supplement, ginkgo biloba, and any nutraceuticals. Occasional chloral hydrate use will be allowed, but discouraged, for insomnia.

•Investigational drugs within the previous month or longer, depending on drug half-life

•Contraindication for MRI scan (e.g., metal in body, claustrophobia)

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.